051 Clinical Serum Biomarker Profiling in TRuE-V1 and TRuE-V2 Vitiligo Studies After Treatment With Ruxolitinib Cream

Abstract

Ruxolitinib cream was developed as a topical treatment for immune-mediated skin diseases, including vitiligo. Ruxolitinib is an equipotent inhibitor of Janus kinase (JAK) 1 and 2. Two identically designed randomized studies, TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were conducted in adolescent and adult participants with nonsegmental vitiligo and depigmentation over ≤10% total body surface area. This analysis examined whether observed pharmacodynamic effects were primarily local or systemic due to the possibility of absorption at the site of local application.